Rigel Reports First Quarter 2020 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Rigel Pharma (RIGL) Reports In-Line Q1 EPS, Revenues Miss
May 5, 2020 4:38 PM EDTRigel Pharma (NASDAQ: RIGL) reported Q1 EPS of $0.13, in-line with the analyst estimate of $0.13. Revenue for the quarter came in at $55.76 million versus the consensus estimate of $56.71 million.
"During these extraordinary times, we continue to execute on our business strategy while maintaining... More
